Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study

Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Inclusion Criteria:

• Pediatric patients under the age of 18 years
• Pediatric patients after HSCT treated with caspofungin
• Pediatric patients after HSCT treated with liposomal amphotericin

Exclusion Criteria:

• Pediatric patients with uncontrolled hematological malignancies
• Pediatric patients with IFI at start of HSCT